GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-0.1925 (-0.2463%)

Growth Price

Undervalued by 110.24%

Stability Price

Overvalued by 34.15%

Company Metrics

  • P/E 6.8437
  • P/S 3.1867
  • P/B 6.6972
  • EPS 11.3940
  • Cash ROIC 49.59%
  • Cash Ratio 1.48
  • Dividend 1.8800 / 2.3600 %
  • Avg. Vol. 10.24M
  • Shares 1.52B
  • Market Cap. 102.90B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Why Gilead Sciences, Inc. (GILD), Valeant Pharmaceuticals Intl Inc (VRX) and ... - 20 hours ago
After having a weekend to think about it, investors decided the prospect and potential impact of rising interest rates may not be as great as presumed following Janet Yellen's comments late last week.
Hot Healthcare Stocks: Valeant Pharmaceuticals Intl Inc (NYSE:VRX ... - Benchmark Monitor
3 Reasons Gilead Sciences Inc. Stock Could Fall
Motley Fool - Aug 25, 2016
One of my largest holdings is Gilead Sciences (NASDAQ:GILD). I've enjoyed nice returns from the big biotech over the last few years.
Piper Jaffray Says Gilead Sciences, Inc. (NASDAQ:GILD) HIV Rivals Have "Come ...
TCC - 5 hours ago
Gilead Sciences, Inc. (NASDAQ:GILD) is still going through multiple hits increasing pressure on the biotech. The latest news dipped the stock to 2% at the close of market as reports published that GlaxoSmithKline plc is diligently working to clinch the ...
GILD Stock: This Could Be a Big Problem for Gilead Sciences, Inc. - Profit Confidential
Gilead Sciences Inc. Stock Is Now Poised To Make A Comeback - Amigobulls
Gilead: A Threat Overlooked
Seeking Alpha - Aug 29, 2016
Government commentary in the U.S. about drug pricing has been a key cause of concern for biotech investors lately. One threat that may be overshadowed for Gilead, though, is its idle cash position. As the companies sales decline, is Gilead patiently ...
Gilead Sciences, Inc: Another Disappointing Quarter Ahead? - Bidness ETC
Why You Should (and Shouldn't) Buy Gilead Sciences, Inc.
Motley Fool - Aug 24, 2016
The declining sales of Gilead Sciences' (NASDAQ:GILD) groundbreaking hepatitis C medicine Harvoni have turned this once high-flying biotech into a battleground stock.
Is Gilead Sciences, Inc. (NASDAQ:GILD) Stock: A Buy? - TCC
Leerink Swann Reiterates Outperform Rating for Gilead Sciences Inc. (GILD) - The Cerbat Gem
Gilead: Forbes Is Salty Over The Vermont Initiative
Seeking Alpha - Aug 29, 2016
Forbes believes focusing on the list price for drugs is a mistake, and questions Vermont's end game. Vermont wants to shine a light on rising drug costs and prompt federal lawmakers to negotiate lower prices.
Gilead Sciences Inc. Stock in 3 Charts
Motley Fool - Aug 9, 2016
Leading antiviral treatments have made Gilead Sciences (NASDAQ:GILD) more profitable than any of its Big Pharma peers, but the stock is trading at bargain-bin prices.
Gilead Sciences, Inc.: A Breakdown Looms for GILD Stock -
Gilead Sciences Inc. (GILD) Stake Decreased by British Columbia Investment ... - The Cerbat Gem
Biotech Stocks Worth a Closer Look: Macrocure (NASDAQ:MCUR), Gilead Sciences ...
The Voice Registrar - 3 hours ago
Gilead Sciences Inc. (NASDAQ:GILD) dropped -2.01% by the close of business day at $78.17. For the current quarter, the 22 Wall Street analysts issuing adjusted earnings per share outlook have a consensus estimate of $2.88/share, which would compare ...
On The Move Sizzling Healthcare Stocks: MACROCURE LTD. (NASDAQ:MCUR ... - WsNews 4investors
Gilead Sciences, Inc. (GILD): European Union Approved HIV Molecule
TCC - Aug 23, 2016
Gilead Sciences, Inc. (NASDAQ:GILD) has announced that the HIV blockbuster drug, Truvada has been granted approval by the European Commission (EU) as once daily dose for the reduction of the infection in uninfected adults.
Gilead gets European Commission approval to market HIV drug - Proactive Investors USA & Canada
Gilead (GILD) Truvada Gets EU Approval for Label Expansion -
Is Gilead Sciences Stock A Buy After The Recent Correction?
Amigobulls - Aug 19, 2016
I think Gilead Sciences, Inc. (NSDQ:GILD) needs to be vindicated after being hammered by investors for more than a year now.
Analyst Views To Note: HP Inc (NYSE:HPQ), Gilead Sciences, Inc. (NASDAQ:GILD) - Review Fortune
Would Gilead Sciences, Inc. (GILD) Need to Split up to Survive? - TCC